Crescent Biopharma, Inc. (CBIO) is a clinical-stage biopharmaceutical company incorporated in the Cayman Islands, inception dated September 19, 2024, with no approved products and no commercial revenue. The liquidation recovery posture for equity is marginally positive on a static balance-sheet basis, driven almost entirely by cash. Total assets are $199.1M against total liabilities of only $15.3M, yielding reported book equity of $183.8M. Under liquidation haircuts, cash of $189.2M recovers at 100% ($189.2M); restricted cash of $0.1M at 100% ($0.1M); prepaid and other current assets of $6.4M at ~50% ($3.2M); PP&E net of $0.9M at ~60% ($0.5M); operating lease ROU asset of $1.4M at 0% ($0); other noncurrent assets of $1.2M at 0-10% (~$0.1M); and the $8.0M intangible asset acquired in Q1 2026 (PaymentsToAcquireIntangibleAssets) at 0% ($0). Estimated liquidation asset recovery is approximately $193.1M. Liabilities at face value: total liabilities $15.3M, including operating lease obligations of $1.5M (undiscounted $1.8M; non-cancellable), accrued liabilities $4.4M, deferred revenue $3.1M (which would not be a cash obligation in wind-down but represents performance obligations that extinguish), employee liabilities $1.8M, and other current items. Net estimated recovery to equity is approximately $177-180M, which exceeds the MFFAIS CLV/LLV/OLV of $173.9M, consistent directionally. The primary driver of this near-neutral-to-positive recovery posture is the large cash cushion from two substantial equity raises: $200M closed at Merger (Q2 2025) and $185M in December 2025. Cash burn was approximately $24M net in Q1 2026, with operating cash outflow of $8.9M and $8.0M deployed for intangible asset acquisition. Accumulated deficit stands at $195.1M on a net loss of $23.3M for Q1 2026. Deferred revenue of $3.1M relates to a collaboration arrangement and is a contingent liability in wind-down rather than a cash obligation, modestly improving recovery. A key risk to recovery is acceleration of burn: Q1 2026 operating expenses were $25.8M annualized, implying a runway of roughly 7-8 quarters at current burn from the $189.2M cash balance. The $8M intangible acquisition (likely a license payment tagged under PaymentsToAcquireIntangibleAssets, with no separately tagged intangible asset on the balance sheet in XBRL — the filing discusses in-licensed IP from Paragon and Kelun but does not tag a separately identified intangible asset line item in XBRL) represents an immediate value impairment under the liquidation lens. The ADC Paragon Option Agreement was terminated March 26, 2026, with settlement via a warrant for 34,566 shares at $13.50; this removes a forward commitment from the liability stack. Operating lease obligations of $1.8M undiscounted are modest. No long-term debt is present on the balance sheet. Series A Preferred Stock ($4.0M carrying value, 2,890 shares outstanding) has liquidation preferences per the Certificate of Designation that would rank ahead of ordinary shares; the carrying value is de minimis relative to total equity but the liquidation preference terms are not separately quantified in XBRL.
▼ Community Notes